Use of a new cross-linked collagen membrane for the treatment of dehiscence-type defects at titanium implants: a prospective, randomized-controlled double-blinded clinical multicenter study

被引:82
|
作者
Becker, Juergen [1 ]
Al-Nawas, Bilal [2 ]
Klein, Marcus O. [2 ]
Schliephake, Hennig [3 ]
Terheyden, Hendrik [4 ]
Schwarz, Frank
机构
[1] Univ Dusseldorf, Dept Oral Surg, W Deutsch Kieferklin, D-40225 Dusseldorf, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Oral & Maxillofacial Surg, Hosp Mainz, Mainz, Germany
[3] Univ Gottingen, Dept Oral & Maxillofacial Surg, Gottingen, Germany
[4] Rotes Kreuz Krankenhaus, Dept Oral & Maxillofacial Surg, Kassel, Germany
关键词
bone regeneration; bone substitutes; clinical research; clinical trials; guided tissue regeneration; GUIDED BONE REGENERATION; DIFFERENT BARRIER MEMBRANES; NONRESORBABLE MEMBRANES; BIORESORBABLE BARRIER; DENTAL IMPLANTS; AUGMENTATION; AUTOGRAFTS;
D O I
10.1111/j.1600-0501.2008.01689.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The aim of the present randomized-controlled double-blinded clinical multicenter study was to assess the use of either a new cross-linked (VN) or a native collagen membrane (BG) for the treatment of dehiscence-type defects at titanium implants. A total of n=54 patients were recruited in four German university clinics. According to a parallel-groups design, dehiscence-type defects at titanium implants were filled with a natural bone mineral and randomly assigned to either VN or BG. Submerged sites were allowed to heal for 4 months. Primary (e.g., changes in defect length - Delta DL, quality of newly formed tissue [0-4] - TQ) and secondary parameters (e.g., membrane exposure, tissue conditions at dehisced sites) were consecutively recorded. Four patients were excluded due to an early wound infection (VN:3; BG:1), and one patient was lost during follow-up (VN). The mean Delta DL was 3.0 +/- 2.5 mm in the VN, and 1.94 +/- 2.13 mm in the BG group. The assessment of TQ revealed comparable mean values in both groups (VN: 3.05 +/- 1.66, BG: 3.46 +/- 1.48). A significant correlation between membrane exposure and inflammation of the adjacent soft tissue was observed in the VN group. In both groups, the mean DL and TQ values were not significantly different at either non-exposed or exposed implant sites. The results of the present study have indicated that VN supported bone regeneration on a level non-inferior to BG. However, in case of a premature membrane exposure, cross-linking might impair soft-tissue healing or may even cause wound infections. To cite this article:Becker J, Al-Nawas B, Klein MO, Schliephake H, Terheyden H, Schwarz F. Use of a new cross-linked collagen membrane for the treatment of dehiscence-type defects at titanium implants. A prospective randomized controlled double-blinded clinical multicenter study.Clin. Oral Impl. Res. 20, 2009; 742-749.doi: 10.1111/j.1600-0501.2008.01689.x.
引用
收藏
页码:742 / 749
页数:8
相关论文
共 29 条
  • [1] Use of a new cross-linked collagen membrane for the treatment of peri-implant dehiscence defects: a randomised controlled double-blinded clinical trial
    Annen, Beat Martin
    Ramel, Christian Felix
    Le, Christoph Hans Franz Haemmer
    Jung, Ronald Ernst
    EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY, 2011, 4 (02) : 87 - 100
  • [2] Comparison of a polyethylene glycol membrane and a collagen membrane for the treatment of bone dehiscence defects at bone level implants-A prospective, randomized, controlled, multicenter clinical trial
    Jung, Ronald Ernst
    Mihatovic, Ilja
    Cordaro, Luca
    Windisch, Peter
    Friedmann, Anton
    Blanco Carrion, Juan
    Sanz Sanchez, Ignacio
    Hallman, Mats
    Quirynen, Marc
    Hammerle, Christoph H. F.
    CLINICAL ORAL IMPLANTS RESEARCH, 2020, 31 (11) : 1105 - 1115
  • [3] Clinical Evaluation of MyoCare in Europe (CEME): study protocol for a prospective, multicenter, randomized, double-blinded, and controlled clinical trial
    Cristina Alvarez-Peregrina
    Miguel Angel Sanchez-Tena
    Clara Martinez-Perez
    Cesar Villa-Collar
    Arne Ohlendorf
    Trials, 24
  • [4] Clinical Evaluation of MyoCare in Europe (CEME): study protocol for a prospective, multicenter, randomized, double-blinded, and controlled clinical trial
    Alvarez-Peregrina, Cristina
    Sanchez-Tena, Miguel Angel
    Martinez-Perez, Clara
    Villa-Collar, Cesar
    Ohlendorf, Arne
    TRIALS, 2023, 24 (01)
  • [5] Assessment of dehydrothermally cross-linked collagen membrane for guided bone regeneration around peri-implant dehiscence defects: a randomized single-blinded clinical trial
    Lee, Jae-Hong
    Lee, Jung-Seok
    Baek, Won-Sun
    Lim, Hyun-Chang
    Cha, Jae-Kook
    Choi, Seong-Ho
    Jung, Ui-Won
    JOURNAL OF PERIODONTAL AND IMPLANT SCIENCE, 2015, 45 (06): : 229 - 237
  • [6] Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: A randomized, double-blinded, active controlled multicenter study
    Lee, W. S.
    Won, C. H.
    Huh, C. H.
    Kang, H.
    Kim, B. J.
    Lee, J. H.
    Kim, W. S.
    TOXICON, 2013, 68 : 116 - 116
  • [7] Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT Study
    Alessandro Pontes-Arruda
    Laércia Ferreira Martins
    Samya Maria de Lima
    Alexandre Marini Isola
    Diogo Toledo
    Ederlon Rezende
    Marcelo Maia
    Gisele Brocco Magnan
    Critical Care, 15
  • [8] Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT Study
    Pontes-Arruda, Alessandro
    Martins, Laercia Ferreira
    de Lima, Samya Maria
    Isola, Alexandre Marini
    Toledo, Diogo
    Rezende, Ederlon
    Maia, Marcelo
    Magnan, Gisele Brocco
    CRITICAL CARE, 2011, 15 (03)
  • [9] Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
    Qin, Shukui
    Bai, Yuxian
    Wang, Zishu
    Chen, Zhendong
    Xu, Ruihua
    Xu, Jianming
    Zhang, Hongmei
    Chen, Jia
    Yuan, Ying
    Liu, Tianshu
    Yang, Lin
    Zhong, Haijun
    Chen, Donghui
    Shen, Lin
    Hao, Chunyi
    Fu, Deliang
    Cheng, Ying
    Yang, Jianwei
    Bai, Xian Hong
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [10] Non-Surgical Treatment of Moderate Periodontal Intrabony Defects With Adjunctive Cross-Linked Hyaluronic Acid: A Single-Blinded Randomized Controlled Clinical Trial
    Iorio-Siciliano, Vincenzo
    Blasi, Andrea
    Mauriello, Leopoldo
    Salvi, Giovanni E.
    Ramaglia, Luca
    Sculean, Anton
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2025, 52 (02) : 310 - 322